HR 1537
114th Congress
House
Health
Blood and blood diseases
Cancer
Child health
Drug safety, medical device, and laboratory regulation
Drug therapy
Hereditary and development disorders
Infectious and parasitic diseases
World health
Advancing Hope Act of 2015
Introduced: March 23, 2015
See on congress.gov
Everywhere this bill has been
3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 27, 2015
Referred to the Subcommittee on Health.
Mar 23, 2015
Referred to the House Committee on Energy and Commerce.
Mar 23, 2015
Introduced in House
Plain-English summary
Advancing Hope Act of 2015
This bill amends the Federal Food, Drug, and Cosmetic Act to expand the priority review voucher program for rare pediatric diseases to include treatments for sickle cell disease and pediatric cancers.
The voucher program is extended by removing the provision terminating the program one year after the Food and Drug Administration's (FDA's) issuance of three rare pediatric disease vouchers.
A voucher may not be issued for a rare pediatric disease product if a voucher was issued for the product as a tropical disease product.
A tropical disease voucher may not be issued for a product that was approved, over two years before submitting an application to the FDA, for commercial marketing by a foreign government to treat a tropical disease.
What's happening now
Referred to the Subcommittee on Health.
Committees of jurisdiction
2